Skandinaviska Enskilda Banken AB publ Invests $647,000 in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) during the 4th quarter, according to its most recent filing with the SEC. The fund bought 38,035 shares of the company’s stock, valued at approximately $647,000. Skandinaviska Enskilda Banken AB publ owned approximately 0.07% of Bicara Therapeutics as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Spire Wealth Management acquired a new stake in Bicara Therapeutics during the fourth quarter valued at approximately $31,000. SG Americas Securities LLC bought a new position in shares of Bicara Therapeutics during the 4th quarter worth approximately $147,000. Cinctive Capital Management LP acquired a new stake in Bicara Therapeutics in the 3rd quarter valued at $229,000. Barclays PLC bought a new stake in Bicara Therapeutics in the third quarter valued at $255,000. Finally, Jane Street Group LLC acquired a new position in Bicara Therapeutics during the third quarter worth $309,000.

Bicara Therapeutics Trading Up 8.7 %

Shares of BCAX stock opened at $13.50 on Tuesday. Bicara Therapeutics Inc. has a 1 year low of $11.10 and a 1 year high of $28.09. The business’s 50 day moving average is $13.15.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Wedbush restated an “outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research note on Wednesday, February 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.01 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Finally, HC Wainwright lifted their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $36.50.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.